Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives

摘要: Medicinal chemistry strategies have contributed to the development, experimental study of and clinical trials assessment first type protein kinase small molecule inhibitor target Janus kinase/Signal Transducers Activators Transcription (JAK/STAT) signaling pathway. The orally administered inhibitor, tofacitinib, is drug JAK/STAT pathway for entry into armamentarium medical therapy rheumatoid arthritis. introduction tofacitinib general rheumatologic practice coupled with increasing understanding that additional cellular signal transduction pathways including mitogen-activated phosphatidylinositide-3-kinase/Akt/mammalian rapamycin as well spleen tyrosine also contribute immune-mediated inflammatory in arthritis makes it likely further development inhibitors will occur near future.